Accendra Health vs Henry Schein
Henry Schein is the larger business, with $13.18bn of revenue in fiscal 2025 against $2.76bn for Accendra Health (4.8 times as much). Henry Schein grew faster (4.0% against 3.1%). Henry Schein kept more of each dollar of sales as profit: a net margin of 3.0% against -39.8%.
| Latest fiscal year | Accendra HealthACH, 2025 | Henry ScheinHSIC, 2025 |
|---|---|---|
| Revenue | $2.76bn | $13.18bn |
| Revenue growth | 3.1% | 4.0% |
| Net income | −$1.10bn | $398m |
| Operating margin | 1.0% | 5.0% |
| Net margin | -39.8% | 3.0% |
| Return on equity | — | 12.0% |
| Free cash flow | −$293m | $573m |
| Cash | $282m | $156m |
| Total debt | $2.05bn | $3.11bn |
| Debt to equity | — | 95.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $10.2m | $850m |
| Employees | 6,500 | 25,000 |
| Market value | $20.0m | $9.69bn |
| Price vs our value range | — | Within our value range |
| Moat score | 17 (Weak) | 58 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 10 sales |